Colorectal cancer (CRC) grading is a critical prognostic factor but remains hampered by inter-observer variability and the privacy constraints of multi-institutional data sharing. While deep learning offers a path to automation, centralized training models conflict with data governance regulations and neglect the diagnostic importance of multi-scale analysis. In this work, we propose a scalable, privacy-preserving federated learning (FL) framework for CRC histopathological grading that integrates multi-scale feature learning within a distributed training paradigm. Our approach employs a dual-stream ResNetRS50 backbone to concurrently capture fine-grained nuclear detail and broader tissue-level context. This architecture is integrated into a robust FL system stabilized using FedProx to mitigate client drift across heterogeneous data distributions from multiple hospitals. Extensive evaluation on the CRC-HGD dataset demonstrates that our framework achieves an overall accuracy of 83.5%, outperforming a comparable centralized model (81.6%). Crucially, the system excels in identifying the most aggressive Grade III tumors with a high recall of 87.5%, a key clinical priority to prevent dangerous false negatives. Performance further improves with higher magnification, reaching 88.0% accuracy at 40x. These results validate that our federated multi-scale approach not only preserves patient privacy but also enhances model performance and generalization. The proposed modular pipeline, with built-in preprocessing, checkpointing, and error handling, establishes a foundational step toward deployable, privacy-aware clinical AI for digital pathology.

RKUM is an R package developed for implementing robust kernel-based unsupervised methods. It provides functions for estimating the robust kernel covariance operator (CO) and the robust kernel cross-covariance operator (CCO) using generalized loss functions instead of the conventional quadratic loss. These operators form the foundation of robust kernel learning and enable reliable analysis under contaminated or noisy data conditions. The package includes implementations of robust kernel canonical correlation analysis (Kernel CCA), as well as the influence function (IF) for both standard and multiple kernel CCA frameworks. The influence function quantifies sensitivity and helps detect influential or outlying observations across two-view and multi-view datasets. Experiments using synthesized two-view and multi-view data demonstrate that the IF of the standard kernel CCA effectively identifies outliers, while the robust kernel methods implemented in RKUM exhibit reduced sensitivity to contamination. Overall, RKUM provides an efficient and extensible platform for robust kernel-based analysis in high-dimensional data applications.

Multi-omics data integration is crucial for understanding complex diseases, yet limited sample sizes, noise, and heterogeneity often reduce predictive power. To address these challenges, we introduce Omics-GAN, a Generative Adversarial Network (GAN)-based framework designed to generate high-quality synthetic multi-omics profiles while preserving biological relationships. We evaluated Omics-GAN on three omics types (mRNA, miRNA, and DNA methylation) using the ROSMAP cohort for Alzheimer's disease (AD) and TCGA datasets for colon and liver cancer. A support vector machine (SVM) classifier with repeated 5-fold cross-validation demonstrated that synthetic datasets consistently improved prediction accuracy compared to original omics profiles. The AUC of SVM for mRNA improved from 0.72 to 0.74 in AD, and from 0.68 to 0.72 in liver cancer. Synthetic miRNA enhanced classification in colon cancer from 0.59 to 0.69, while synthetic methylation data improved performance in liver cancer from 0.64 to 0.71. Boxplot analyses confirmed that synthetic data preserved statistical distributions while reducing noise and outliers. Feature selection identified significant genes overlapping with original datasets and revealed additional candidates validated by GO and KEGG enrichment analyses. Finally, molecular docking highlighted potential drug repurposing candidates, including Nilotinib for AD, Atovaquone for liver cancer, and Tecovirimat for colon cancer. Omics-GAN enhances disease prediction, preserves biological fidelity, and accelerates biomarker and drug discovery, offering a scalable strategy for precision medicine applications.